Shortly following the announcement of its acquisition of Syndivia’s ADC, GSK entered into a worldwide exclusive license agreement with Empirico for its leading clinical-stage respiratory disease ...

Under the deal, France-based Syndivia will receive an upfront payment, as well as development and commercial milestone payments, totaling up to £268 million. ・GSK, meanwhile, will undertake ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer drugs in the third quarter.

GSK acquires exclusive rights from Syndivia for antibody-drug conjugate in prostate cancer: London, UK Tuesday, October 28, 2025, 09:00 Hrs [IST] GSK plc and Syndivia, a private b ...

GSK said the forecasts were “inclusive of tariffs enacted thus far and indicated potential European tariffs' impact of 15 per ...

A bold guidance raise, fresh FDA approval, and pipeline deals set the stage for GSK's post-Walmsley transformation.

GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...

Clarient Diagnostic Services, an affiliate of GE Healthcare, has entered into a collaboration agreement with GlaxoSmithKline that is aimed at improving cancer patients’ access to diagnostic testing.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...